Literature DB >> 17663643

Treating neurodegeneration by modifying mitochondria: potential solutions to a "complex" problem.

Russell H Swerdlow1.   

Abstract

Mitochondria function differently in aged brains than they do in young brains. Consistently reported changes include reduced electron transport chain (ETC) enzyme activities, reduced phosphorylation of ADP, and increased reactive oxygen species (ROS) production. Various neurodegenerative diseases are also associated with changes in mitochondrial function, and these changes both recapitulate and extend those seen in "normal" aging. Unfortunately, attempts to treat neurodegenerative diseases by treating mitochondria-related pathology have thus far minimally impacted affected patients. A better understanding of how mitochondrial function changes in aging and neurodegenerative diseases, though, now suggests new approaches to mitochondrial therapy may prove more efficacious. Increasing ETC capacity, increasing oxidative phosphorylation, or decreasing mitochondrial ROS may yet prove useful for the treatment of brain aging and neurodegenerative diseases, and accomplishing this seems increasingly feasible. This review will discuss the role of mitochondrial function and dysfunction in aging and neurodegenerative diseases, and will focus on potential treatment strategies.

Entities:  

Mesh:

Year:  2007        PMID: 17663643     DOI: 10.1089/ars.2007.1676

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  39 in total

Review 1.  The Alzheimer's disease mitochondrial cascade hypothesis.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  Biochim Biophys Acta       Date:  2013-09-23

Review 3.  The neurodegenerative mitochondriopathies.

Authors:  Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 4.  Mitochondrial medicine for aging and neurodegenerative diseases.

Authors:  P Hemachandra Reddy
Journal:  Neuromolecular Med       Date:  2008-06-20       Impact factor: 3.843

5.  Oxaloacetate activates brain mitochondrial biogenesis, enhances the insulin pathway, reduces inflammation and stimulates neurogenesis.

Authors:  Heather M Wilkins; Janna L Harris; Steven M Carl; Lezi E; Jianghua Lu; J Eva Selfridge; Nairita Roy; Lewis Hutfles; Scott Koppel; Jill Morris; Jeffrey M Burns; Mary L Michaelis; Elias K Michaelis; William M Brooks; Russell H Swerdlow
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

Review 6.  Alzheimer's disease pathologic cascades: who comes first, what drives what.

Authors:  Russell H Swerdlow
Journal:  Neurotox Res       Date:  2011-09-13       Impact factor: 3.911

Review 7.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012

8.  Mitochondrial oxidative stress and dysfunction in rat brain induced by carbofuran exposure.

Authors:  Sukhdev Singh Kamboj; Vikas Kumar; Amit Kamboj; Rajat Sandhir
Journal:  Cell Mol Neurobiol       Date:  2008-03-14       Impact factor: 5.046

Review 9.  VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis.

Authors:  Leo Veenman; Yulia Shandalov; Moshe Gavish
Journal:  J Bioenerg Biomembr       Date:  2008-06       Impact factor: 2.945

Review 10.  Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease.

Authors:  P Hemachandra Reddy
Journal:  Exp Neurol       Date:  2009-04-07       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.